cGMP: Metabolism and Appetite Modulation
ConditionHealthy
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversidade Nova de Lisboa
About this trial
Phenylketonuria is an inborn error of phenylalanine metabolism. Although the phenylalanine-restricted diet is recognized as the mainstay of therapy, little is known about the impact of protein substitutes on the metabolism of patients with phenylketonuria.
Therefore, the aim of this project is to study the impact of acute ingestion of casein glycomacropeptide supplemented with amino acids (cCGMP-AAs) alone or in combination with two different meals on amino acid absorption kinetics, glycaemic and insulinemic response, and on acute markers of appetite control.
The main findings of this project will bring new insights into the dietary management of these patients, which may lead to improvements in protein substitutes formulations.
Eligibility criteria
Qualifiers
Men or women
Adults (age ≥ 18 years)
Body Mass Index (BMI) between 18.5-25.0 kg/m2
Filling informed consent
Disqualifiers
Clinically significant illness
Have changed frequency, duration, or intensity of physical activity in the last month
Taking protein supplements
Pregnant or breastfeeding
Trial design
Treatments tested in this trial
- cGMP-AAs alone (20 g of protein equivalent)
- cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 160 g of unpeeled apple
- cGMP-AAs (20 g of protein equivalent) + 50 g of low-protein bread + 10 g of olive oil
Treatment groups
15 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov